Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Phase 2 trial records — page 4

92 records at phase 2.

Showing 0 records on this page

Records

92 documents · page 4 of 4

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
GHKCU-TOPICAL-2GHK-CuPhase 2ReportedRandomised, double-blind, placebo-controlled2007Low
PRAM-OBESITY-PH2PramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled4112007Low
PRAM-OBESITY-PH2-OLEprogramme recordPramlintidePhase 2ReportedSingle-arm open-label2007Very low
PRAM-OBESITY-PH2-ELDERLYprogramme recordPramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-BIOMARKERprogramme recordPramlintidePhase 2ReportedRandomised, double-blind, placebo-controlled2007Very low
PRAM-OBESITY-PH2-ADHERENCEprogramme recordPramlintidePhase 2ReportedObservational2007Very low
GHKCU-TOPICAL-1GHK-CuPhase 2ReportedRandomised, double-blind, placebo-controlled2005Low
TA1-VACCINE-ELDERLYThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Moderate
TA1-VACCINE-ELDERLY-BODY-COMPprogramme recordThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Very low
TA1-VACCINE-ELDERLY-QOLprogramme recordThymosin alpha-1Phase 2ReportedRandomised, double-blind, placebo-controlled1998Very low
HEX-PH2-ELDERLYHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Low
HEX-PH2-ELDERLY-QOLprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-BODY-COMPprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
HEX-PH2-ELDERLY-ELDERLYprogramme recordHexarelinPhase 2ReportedRandomised, double-blind, placebo-controlled1997Very low
PETRE-PH2-OBESITYPetrelintidePhase 2OngoingRandomised, double-blind, placebo-controlledNot rated
BPC-PH2-UCBPC-157Phase 2No retrievable reportRandomised, double-blind, placebo-controlledNot rated
PETRE-PH2-OBESITY-BODY-COMPprogramme recordPetrelintidePhase 2OngoingRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-BODY-COMPprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low
PETRE-PH2-OBESITY-QOLprogramme recordPetrelintidePhase 2OngoingRandomised, double-blind, placebo-controlledVery low
BPC-PH2-UC-QOLprogramme recordBPC-157Phase 2ReportedRandomised, double-blind, placebo-controlledVery low

page 4 of 4

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.